Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothée Olivier

Showing results (1-10 of 93) with videos related to

Pageof 10
Sort By:
Revue Medicale Suisse|May 17, 2024
[Interpreting a randomized trial in oncology: Key points for the clinician]Timothée Olivier
European Journal of Cancer (Oxford, England : 1990)|November 22, 2025
Identifying informative censoring from censoring patterns across successive follow-upsTimothée Olivier
Translational Oncology|February 23, 2022
The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDATimothée Olivier, Vinay Prasad
Translational Oncology|July 5, 2022
Amivantamab and Mobocertinib in Exon 20 insertions EGFR Mutant Lung Cancer, Challenge To The Current GuidelinesTimothée Olivier, Vinay Prasad
European Journal of Cancer (Oxford, England : 1990)|May 13, 2022
FDA precedents in drug approvals: Contradiction in promoting more treatment optionsTimothée Olivier, Vinay Prasad
The Lancet. Oncology|December 1, 2023
Tumor Treating Fields therapy in metastatic non-small-cell lung cancerTimothée Olivier, Alfredo Addeo
European Journal of Cancer (Oxford, England : 1990)|August 16, 2025
When suboptimal post-protocol care in oncology trials is rewardedGiuseppe Salfi, Timothée Olivier
European Journal of Cancer (Oxford, England : 1990)|February 21, 2024
Equal censoring but still informative: When the reasons for censoring differ between treatment armsTimothée Olivier, Vinay Prasad
Journal of Cancer Policy|March 10, 2025
Adding adjuvant drugs from distinct breast cancer trialsTimothée Olivier, Vinay Prasad
Translational Oncology|April 15, 2024
Neoadjuvant followed by adjuvant pembrolizumab in melanoma: time biases in the data analysis of the SWOG S1801 trialTimothée Olivier, Vinay Prasad
Pageof 10

Showing results (1-10 of 93) with videos related to

Sort By:
Pageof 10
Revue Medicale Suisse|May 17, 2024
[Interpreting a randomized trial in oncology: Key points for the clinician]Timothée Olivier
European Journal of Cancer (Oxford, England : 1990)|November 22, 2025
Identifying informative censoring from censoring patterns across successive follow-upsTimothée Olivier
Translational Oncology|February 23, 2022
The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDATimothée Olivier, Vinay Prasad
Translational Oncology|July 5, 2022
Amivantamab and Mobocertinib in Exon 20 insertions EGFR Mutant Lung Cancer, Challenge To The Current GuidelinesTimothée Olivier, Vinay Prasad
European Journal of Cancer (Oxford, England : 1990)|May 13, 2022
FDA precedents in drug approvals: Contradiction in promoting more treatment optionsTimothée Olivier, Vinay Prasad
The Lancet. Oncology|December 1, 2023
Tumor Treating Fields therapy in metastatic non-small-cell lung cancerTimothée Olivier, Alfredo Addeo
European Journal of Cancer (Oxford, England : 1990)|August 16, 2025
When suboptimal post-protocol care in oncology trials is rewardedGiuseppe Salfi, Timothée Olivier
European Journal of Cancer (Oxford, England : 1990)|February 21, 2024
Equal censoring but still informative: When the reasons for censoring differ between treatment armsTimothée Olivier, Vinay Prasad
Journal of Cancer Policy|March 10, 2025
Adding adjuvant drugs from distinct breast cancer trialsTimothée Olivier, Vinay Prasad
Translational Oncology|April 15, 2024
Neoadjuvant followed by adjuvant pembrolizumab in melanoma: time biases in the data analysis of the SWOG S1801 trialTimothée Olivier, Vinay Prasad
Pageof 10